Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy (Q40072336)

17 September 2017

title

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy (English)

1 reference

17 September 2017

0 references

1 reference

Newcastle disease virus

object named as

Newcastle disease virus

1 reference

Janke M

1

1 reference

17 September 2017

Peeters B

2

1 reference

17 September 2017

de Leeuw O

3

1 reference

17 September 2017

Moorman R

4

1 reference

17 September 2017

Arnold A

5

1 reference

17 September 2017

Fournier P

6

1 reference

17 September 2017

Schirrmacher V

7

1 reference

17 September 2017

publication date

4 October 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

23

1 reference

17 September 2017

page(s)

1639-1649

1 reference

Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Newcastle disease virus (NDV): brief history of its oncolytic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Danger signals: SOS to the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Cell type-specific involvement of RIG-I in antiviral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Amplicons as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Type I interferons in host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Links between innate and adaptive immunity via type I interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

The double-stranded RNA-dependent protein kinase PKR: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

7 January 2021

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

7 January 2021

Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

7 January 2021

Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

7 January 2021

Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With AutologousGM-CSF–Transduced Tumor Cells in Metastatic Melanoma Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3303026

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3303026

1 reference

Dimensions Publication ID

17 September 2017

1003177988

0 references

1 reference